Cargando…
Potential of Quinine Sulfate for COVID-19 Treatment and Its Safety Profile: Review
The coronavirus disease 2019 (COVID-19) pandemic is currently the largest and most serious health crisis in the world. There is no definitive treatment for COVID-19. Vaccine administration has begun in various countries, but no vaccine is 100% effective. Some people are not protected after vaccinati...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665662/ https://www.ncbi.nlm.nih.gov/pubmed/34908881 http://dx.doi.org/10.2147/CPAA.S331660 |
_version_ | 1784614055748567040 |
---|---|
author | Latarissa, Irma Rahayu Barliana, Melisa Intan Meiliana, Anna Lestari, Keri |
author_facet | Latarissa, Irma Rahayu Barliana, Melisa Intan Meiliana, Anna Lestari, Keri |
author_sort | Latarissa, Irma Rahayu |
collection | PubMed |
description | The coronavirus disease 2019 (COVID-19) pandemic is currently the largest and most serious health crisis in the world. There is no definitive treatment for COVID-19. Vaccine administration has begun in various countries, but no vaccine is 100% effective. Some people are not protected after vaccination, and there are some groups of people who cannot be vaccinated therefore, research on COVID-19 treatment still needs to be done. Of the several drugs under study, chloroquine (CQ) and hydroxychloroquine (HCQ) are quite controversial, although they have good activity against SARS-CoV-2, both drugs have serious side effects. Indonesia with its wealth of natural ingredients has one potential compound, quinine sulfate (QS), which has the same structure and activity as CQ and HCQ and a better safety profile. The aim of this article was to review the potential of QS against the SARS-Cov-2 virus and outline its safety profile. We conclude that QS has the potential to be developed as a COVID-19 treatment with a better safety profile than that of CQ and HCQ. |
format | Online Article Text |
id | pubmed-8665662 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-86656622021-12-13 Potential of Quinine Sulfate for COVID-19 Treatment and Its Safety Profile: Review Latarissa, Irma Rahayu Barliana, Melisa Intan Meiliana, Anna Lestari, Keri Clin Pharmacol Review The coronavirus disease 2019 (COVID-19) pandemic is currently the largest and most serious health crisis in the world. There is no definitive treatment for COVID-19. Vaccine administration has begun in various countries, but no vaccine is 100% effective. Some people are not protected after vaccination, and there are some groups of people who cannot be vaccinated therefore, research on COVID-19 treatment still needs to be done. Of the several drugs under study, chloroquine (CQ) and hydroxychloroquine (HCQ) are quite controversial, although they have good activity against SARS-CoV-2, both drugs have serious side effects. Indonesia with its wealth of natural ingredients has one potential compound, quinine sulfate (QS), which has the same structure and activity as CQ and HCQ and a better safety profile. The aim of this article was to review the potential of QS against the SARS-Cov-2 virus and outline its safety profile. We conclude that QS has the potential to be developed as a COVID-19 treatment with a better safety profile than that of CQ and HCQ. Dove 2021-12-06 /pmc/articles/PMC8665662/ /pubmed/34908881 http://dx.doi.org/10.2147/CPAA.S331660 Text en © 2021 Latarissa et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Latarissa, Irma Rahayu Barliana, Melisa Intan Meiliana, Anna Lestari, Keri Potential of Quinine Sulfate for COVID-19 Treatment and Its Safety Profile: Review |
title | Potential of Quinine Sulfate for COVID-19 Treatment and Its Safety Profile: Review |
title_full | Potential of Quinine Sulfate for COVID-19 Treatment and Its Safety Profile: Review |
title_fullStr | Potential of Quinine Sulfate for COVID-19 Treatment and Its Safety Profile: Review |
title_full_unstemmed | Potential of Quinine Sulfate for COVID-19 Treatment and Its Safety Profile: Review |
title_short | Potential of Quinine Sulfate for COVID-19 Treatment and Its Safety Profile: Review |
title_sort | potential of quinine sulfate for covid-19 treatment and its safety profile: review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665662/ https://www.ncbi.nlm.nih.gov/pubmed/34908881 http://dx.doi.org/10.2147/CPAA.S331660 |
work_keys_str_mv | AT latarissairmarahayu potentialofquininesulfateforcovid19treatmentanditssafetyprofilereview AT barlianamelisaintan potentialofquininesulfateforcovid19treatmentanditssafetyprofilereview AT meilianaanna potentialofquininesulfateforcovid19treatmentanditssafetyprofilereview AT lestarikeri potentialofquininesulfateforcovid19treatmentanditssafetyprofilereview |